Cargando…

Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors

We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only be...

Descripción completa

Detalles Bibliográficos
Autores principales: Šála, Michal, Kögler, Martin, Plačková, Pavla, Mejdrová, Ivana, Hřebabecký, Hubert, Procházková, Eliška, Strunin, Dmytro, Lee, Gary, Birkus, Gabriel, Weber, Jan, Mertlíková-Kaiserová, Helena, Nencka, Radim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127540/
https://www.ncbi.nlm.nih.gov/pubmed/27090557
http://dx.doi.org/10.1016/j.bmcl.2016.04.002
_version_ 1783516382696046592
author Šála, Michal
Kögler, Martin
Plačková, Pavla
Mejdrová, Ivana
Hřebabecký, Hubert
Procházková, Eliška
Strunin, Dmytro
Lee, Gary
Birkus, Gabriel
Weber, Jan
Mertlíková-Kaiserová, Helena
Nencka, Radim
author_facet Šála, Michal
Kögler, Martin
Plačková, Pavla
Mejdrová, Ivana
Hřebabecký, Hubert
Procházková, Eliška
Strunin, Dmytro
Lee, Gary
Birkus, Gabriel
Weber, Jan
Mertlíková-Kaiserová, Helena
Nencka, Radim
author_sort Šála, Michal
collection PubMed
description We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only bear a small substituent to maintain the inhibitory activity, position 2 is opened for extensive modification and can accommodate even substituted phenyl rings without the loss of PI4K IIIβ inhibitory activity. These empirical observations nicely correlate with the results of our docking study, which suggests that position 2 directs towards solution and can provide the necessary space for the interaction with remote residues of the enzyme, whereas the cavity around position 8 is strictly limited. The obtained compounds have also been subjected to antiviral screening against a panel of (+)ssRNA viruses.
format Online
Article
Text
id pubmed-7127540
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71275402020-04-08 Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors Šála, Michal Kögler, Martin Plačková, Pavla Mejdrová, Ivana Hřebabecký, Hubert Procházková, Eliška Strunin, Dmytro Lee, Gary Birkus, Gabriel Weber, Jan Mertlíková-Kaiserová, Helena Nencka, Radim Bioorg Med Chem Lett Article We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only bear a small substituent to maintain the inhibitory activity, position 2 is opened for extensive modification and can accommodate even substituted phenyl rings without the loss of PI4K IIIβ inhibitory activity. These empirical observations nicely correlate with the results of our docking study, which suggests that position 2 directs towards solution and can provide the necessary space for the interaction with remote residues of the enzyme, whereas the cavity around position 8 is strictly limited. The obtained compounds have also been subjected to antiviral screening against a panel of (+)ssRNA viruses. Elsevier Ltd. 2016-06-01 2016-04-05 /pmc/articles/PMC7127540/ /pubmed/27090557 http://dx.doi.org/10.1016/j.bmcl.2016.04.002 Text en © 2016 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Šála, Michal
Kögler, Martin
Plačková, Pavla
Mejdrová, Ivana
Hřebabecký, Hubert
Procházková, Eliška
Strunin, Dmytro
Lee, Gary
Birkus, Gabriel
Weber, Jan
Mertlíková-Kaiserová, Helena
Nencka, Radim
Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title_full Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title_fullStr Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title_full_unstemmed Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title_short Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
title_sort purine analogs as phosphatidylinositol 4-kinase iiiβ inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127540/
https://www.ncbi.nlm.nih.gov/pubmed/27090557
http://dx.doi.org/10.1016/j.bmcl.2016.04.002
work_keys_str_mv AT salamichal purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT koglermartin purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT plackovapavla purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT mejdrovaivana purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT hrebabeckyhubert purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT prochazkovaeliska purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT strunindmytro purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT leegary purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT birkusgabriel purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT weberjan purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT mertlikovakaiserovahelena purineanalogsasphosphatidylinositol4kinaseiiibinhibitors
AT nenckaradim purineanalogsasphosphatidylinositol4kinaseiiibinhibitors